Free Newsletter
Irish health exec raises doc-industry question
Will the microscope on doc-pharma relationships move to Ireland? The country's Health Service chief is proposing that the government consider somehow regulating financial ties between doctors and drugmakers. A statement from Ireland's HSE said CEO Brendan Drumm believes that "it is worth considering whether some degree of regulation in this country would benefit the drug industry and the medical profession."
In his letter to the Irish Department of Health secretary general, Drumm cited a self-regulatory code of conduct recently authorized by Australia's Competition and Consumer Commission. That code offers rules for pharma sponsorship of medical conferences, pharma-paid travel and lodging, and drugmaker promotions to doctors.
The Irish pharma trade group already has its own code of marketing practices, which sets out some guidelines for ethical behavior, emphasizing the industry's role as an "educator" of doctors about drugs and treatments. If the government gets involved, however, those guidelines are likely to change. And with the financial ties among docs and industry getting more and more attention these days, the Irish government's involvement may come soon.
- read the story from the Irish Times
Related Articles:
AstraZeneca joins doc-disclosure movement
Pharma, academia ties difficult to unwind
Institute of Medicine: Time to nix pharma gifts
Merck chief: Pharma, regain America's trust!
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: